Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

Figure 2

BTLA expression in B (CD19+) and T (CD3+) cell populations in unstimulated and stimulated cells from CLL patients and controls. The expression of BTLA on the surface of lymphocytes from patients and healthy donors was determined by flow cytometry. (a) The frequency of BTLA+ cells within circulating and in vitro stimulated CD19+ cells in CLL patients and controls is shown. (b) The frequency of BTLA+ cells within circulating and in vitro stimulated CD3+ cells in CLL patients and controls is shown. (c) The mean fluorescence intensity (MFI) of BTLA molecules on the surface of PB and in vitro stimulated CD19+ cells in CLL patients and controls is shown. (d) The mean fluorescence intensity (MFI) of BTLA molecules on the surface of PB and in vitro stimulated CD3+ cells in CLL patients and controls is shown. The horizontal lines show the median values, and the boxes exhibit interquartile ranges.